Johnson & Johnson's

Johnson & Johnson is earmarking nearly USD 9 billion to cover allegations that its baby power containing talc caused cancer, more than quadrupling the amount that the company had previously set aside to pay for its potential liability. Under a proposal announced Tuesday, a J&J subsidiary will re-file for Chapter 11 bankruptcy protection and seek court approval for a plan that would result in one of the largest product-liability settlements in U.S. history. The USD 8.9 billion that J&J would transfer to the subsidiary, LTL Management, would be payable over the next 25 years. The amount is up from the USD 2 billion that the New Brunswick, New Jersey, company set aside in October 2021. The revised amount is being backed by more than 60,000 parties that have filed lawsuits alleging harm from J&J talcum powder, according to the company. J&J isn't admitting any wrongdoing as part of the proposed settlement, a point that company executive emphasised in a Tuesday statement

Around November, the ICMR sought the drug regulator's nod for phase-3 trials of a vaccine candidate it developed with drugmakers SII and Panacea Biotec

The Bombay High Court on Wednesday ordered for fresh testing of Johnson & Johnson baby powder samples and permitted the company to manufacture the product but to not sell it, as per the Maharashtra government order. The company had filed a petition challenging two orders of the state government- one dated September 15 cancelling the license and the second dated September 20 ordering to immediately stop manufacturing and sale of the company's baby powder product. The orders were passed by the joint commissioner and licensing authority of the state Food and Drug Administration (FDA). The government based its orders on the report of the Central Drug Laboratory in Kolkata, which found the powder containing higher pH level than prescribed. A division bench of Justices S V Gangapurwala and S G Dige on Wednesday directed the FDA to collect fresh samples from the company's factory in Mulund area of Mumbai within three days. The sample would then be sent to three laboratories - two ...

Pharmaceuticals firm Hetero on Monday said it has acquired the manufacturing plant of Johnson & Johnson at Penjerla in Telangana and will invest additional Rs 600 crore on its upgradation. According to sources, the company has acquired the plant for Rs 130 crore. The facility is spread across 55.27 acres and will be Hetero's flagship sterile pharmaceutical and biologics manufacturing unit and will generate 2,000 new jobs, the company said in a statement. "We are committed to an investment upwards of USD 75 million, (approximately Rs 600 crore) to upgrade and enhance existing facilities at the site and expand manufacturing of our global biologics and sterile pharmaceutical products," Hetero Managing Director Vamsi Krishna Bandi said. Hetero said the brownfield manufacturing facility together with land, plant and machinery has been acquired from Johnson & Johnson Pvt Ltd in a slump sale without disclosing the financial details. PwC acted as the exclusive financial advisor to the

After 38,000 serious allegations, Johnson and Johnson's talc-based baby powder will stop international sales from 2023. The product has already been discontinued in the US and Canada

Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine. "Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing," the US embassy in India said in a tweet on Wednesday. India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years. The Drugs Controller General of India (DCGI) recently approved Corbevax as a precaution dose for those aged 18 and above.

India had, in May, scrapped local trials for 'well-established' foreign coronavirus vaccines as it tried to hasten vaccination rollouts to fight a second wave of infections.

Japan's daily cases top 10,000 for the first time, Most South Africans don't want Covid shot, and other pandemic-related news across the globe

WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday declined to hear Johnson & Johnson's bid to overturn a $2.12 billion damages award to women who blamed their ovarian cancer on asbestos in the company's baby powder and other talc products.

The virus has killed almost 121,000 people across Africa and infected 4.18 million

The deal with J&J comes just days after the US government authorized its one-dose Covid-19 vaccine and as the company looks to increase its production

AstraZeneca's US trial was paused on September 6 after a report of a serious neurological illness, believed to be transverse myelitis, in a participant in the company's UK trial

J&J has already received $1 billion in funding from the US

The miscalculation came when he was assessing various costs to the state to deal with addiction and prevention issues stemming from opioids

(Reuters) - Ever since Johnson & Johnson disclosed this month that a government test had turned up asbestos in its Baby Powder, the company has attacked the validity of the result.

J&J had recorded a partial impairment charge of about $630 million related to the treatment in the third quarter last year after having suspended trials in August.

A lawsuit was filed on September 26 accusing the company of "negligent conduct" in making and marketing its baby powder